Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. - 3. (canceled)

- 4. (original) A host-vector system, which comprises
 - a. A host chromosome comprising
 - an activatible control sequence, wherein the activatible control sequence is activatible by an inducer;
 - at least one sequence that encodes a repressor, wherein the sequence is operably-linked to the activatible control sequence; and
 - at least one essential gene, wherein the essential gene encodes a
 polypeptide that is necessary for synthesis of a rigid layer of a cell wall of
 a prokarvote, and wherein the essential gene is inactivated;

AND

- b. At least one vector comprising
 - a prokaryotic activator-promoter sequence;
 - ii. at least one origin of replication (ori);
 - a first regulatable prokaryotic promotor sequence, wherein the first regulatable prokaryotic promotor sequence is repressible by a first repressor;
 - a second regulatable prokaryotic promotor sequence, wherein the second regulatable prokaryotic promotor sequence is repressible by a second repressor:
 - at least one essential gene, wherein the essential gene is necessary for synthesis of a rigid layer of a cell wall of a prokaryote;

2

4849549.1

Appl, No. 10/526,365

Response to Office Action dated June 25, 2008

Atty. Docket No: 56029-53712

vi. at least one transcription terminator sequence; and

vii. a site for insertion of a gene encoding a desired gene product.

5. - 7. (canceled)

8. (previously presented) The host-vector system of claim 4, wherein the host-vector system

comprises two vectors, and wherein the desired gene product and the essential gene on one vector is different from the desired gene product and the essential gene on the other

vector.

9. - 14. (canceled)

15. (previously presented) A microorganism comprising the host-vector system of claim 4.

16. - 17. (canceled)

18. (original) A vaccine comprising the microorganism of claim 15.

19. - 20. (canceled)

(withdrawn) A method for delivery of a desired gene product to a eukaryotic host, which
comprises administering to the eukaryotic host a microorganism of claim 15, wherein a

21 0 030.

comprises administrating to the entirely one hours a service of

prokaryote expresses the desired gene product.

22. - 46. (canceled)

47. (previously presented) The host-vector system of claim 4, further comprising a gene

encoding a desired gene product.

4849549.1

- (previously presented) The host-vector system of claim 47, wherein the gene encodes an antigen.
- (previously presented) The host-vector system of clam 48, wherein the antigen is from a bacterial, viral, fungal, or parasitic pathogen.
- (previously presented) The host-vector system of claim 49, wherein the antigen is from Eimeria, HBV, or streptococcus pneumoniae.
- (previously presented) The host-vector system of claim 4, wherein the essential gene is asd. murA. dapA. or alr.
- (previously presented) The host-vector system of claim 4, wherein the essential gene has a mutation that changes an ATG start codon to GTG or TTG.
- (previously presented) The host-vector system of claim 4, wherein the terminator sequence is rrFG.
- (previously presented) The host-vector system of claim 4, comprising at least three terminator sequences.
- (previously presented) The host-vector system of claim 4, comprising at least two
 essential genes.
- (previously presented) The host-vector system of claim 4, wherein the inducer is arabinose
- 57. (withdrawn) The method of claim 21, wherein the eukaryotic host is a vertebrate.

Atty. Docket No: 56029-53712

 (withdrawn) The method of claim 57, wherein the vertebrate is a human, mouse, rat, or bird

- (withdrawn) The method of claim 21, wherein the microorganism colonizes a lymphoid tissue of the eukaryotic host.
- (withdrawn) The method of claim 59, wherein the lymphoid tissue is in a liver, spleen,
 GALT, or mesenteric lymph node.
- (previously presented) The host-vector system of claim 4, further comprising a mutation in a gene to enhance immunogenicity, wherein the mutation is ΔendA2311, ΔrelA1123, ΔaraE25, ΔaraBAD1923, ΔaraBAD23, Δgmd-11, or Δgmd-fcl-26.
- 62. (withdrawn) A method of immunizing a poultry against coccidiosis, comprising
 - Administering to the poultry a microorganism comprising the host-vector system of claim 48, wherein the antigen is from Eimeria; and

Annual Control

- Eliciting an immune response in the poultry.
- 63. (withdrawn) The method of claim 62, wherein the poultry is a chicken.
- 64. (previously presented) The vaccine of claim 18, wherein the vector is a BAC vector.

4849549.1 5